Cardiology Research Fellow | Imperial College London
London, England
Joined July 2022
- Tweets39
- Following112
- Followers148
- Likes165
Florentina Simader retweeted
Check out @EuroInterventio Turning Point episode 2 with @rallamee
🎧 eurointervention.pcronline.c…
@DFCapodanno @PCRonline
@ShrillaB @mirvatalasnag @WomenAs1 @rajkumar_chris @ProfDFrancis @MikeFoley89 @fiyyazAJ @ShaynaChotai @FloSimader @mshunshin @NievesGonzalo1 @nickaram @Hragy
Episode 2 of Turning Point is here!
Host @aayshacader speaks with @rallamee about her path from clinician to pioneering researcher.
From early grant struggles to leading the ORBITA trial, discover how resilience, courage & teamwork shaped her career.
Florentina Simader retweeted
Michael foley presenting orbita 2 analysis showing that ffr and ifr predict angina benefit from pci.
Absolute values matter more than dichotimous cutoff. I would personally like to see how microvascular function fits into this @rallamee @mirvatalasnag @OKhaliqueMD @Hragy @ColletCarlos @DrPeterOKane @gap0161prevent @TTelila @alaide_chief #TCT2024
Florentina Simader retweeted
Watch This Week's Episode of OPCI Journal Club: “ORBITA-STAR Trial and the ORBITA II Symptoms Analysis” presented by @rallamee @rajkumar_chris and @FloSimader. Joined by panelists @djc795 @JWMoses @ESHLOF and Dr. Lawrence Garcia. opci.live/journal-club/ #cardiotwitter
Florentina Simader retweeted
Just in case you thought the ORBITA team had gone on summer vacation… The first ORBITA-MOON case was completed yesterday. Another n-of-1 trial that might have some interesting results. Well done @ShaynaChotai on achieving the first of many big milestones during your PhD!
Florentina Simader retweeted
#cvCAD patients who have angina are more likely to achieve symptom relief from #PCI, according to an analysis of the ORBITA-2 trial in #JACC. bit.ly/3V3K3LW @TCTMD @TCTMD_Caitlin
Florentina Simader retweeted
ORBITA-2: Angina Phenotype Strongly Predicts PCI Response @rallamee @FloSimader
tctmd.com/news/orbita-2-angi…
Florentina Simader retweeted
.@FloSimader on #ORBITA-2 at #EuroPCR:
📌Poor correlation between symptoms & disease severity
📌Symptom nature is a powerful predictor of the placebo-controlled efficacy of #PCI
📌Rose angina & typical angina are excellent predictors of the placebo-controlled efficacy of PCI
📌Other symptoms such as SOB are poor predictors of the placebo-controlled efficacy of PCI
Florentina Simader retweeted
#ICYMI @aayshacader asked @rallamee & @FloSimader to summarize the symptom-stratified analysis of ORBITA-2 presented at #EuroPCR!
Florentina Simader retweeted
The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in @JACCJournals by @FloSimader and @rajkumar_chris. PCI isn’t a therapy for all symptoms, it’s a therapy for angina @rallamee @mshunshin
Florentina Simader retweeted
🔥 Important new insights from ORBITA-2 study presented today at #EuroPCR
👉🏼 More angina symptoms do not necessarily reflect more extended coronary disease
👉🏼 The clinical history is a strong predictor of the efficacy of PCI
🚨Interroge your patients!
@PCRonline @rallamee
Florentina Simader retweeted
#EuroPCR #JACC LBCT SimPub: #ORBITA-2 symptom-stratified analysis - Although symptom severity & nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of #PCI. bit.ly/3QK76cj
@FloSimader @rallamee
Florentina Simader retweeted
…and this:
O R B I T A 2:
symptom-stratified analysis
⏰ 15/05 8:30
📍 Theatre Havane
👋 Florentina Simader
@rallamee
#EuroPCR 2024
#CoronaryPhysiology
#BypassSurgery
#PercutaneousCoronaryIntervention
#LateBreakingScience
Looking forward to this:
🔥 F A M E 3 analysis:
C A B G vs PCI
C O S T - effectivenes 💰💰💰
👋 Frederik Zimmermann
@wfearonmd
⏰ 08:30 May 15
📍 Theatre Havane
Florentina Simader retweeted
We Are Chasing Impact, Not Impact Factor—my video w/my vision for #JACC. I was frustrated with the peer-reviewed journal establishment, and now I am part of it. So…can we create author-centricity, and high-value for society. @JACCJournals youtube.com/watch?v=bbHSR6gS…
Florentina Simader retweeted
Q: Does blinding matter in RCTs of surgical procedures? A: Depends on the endpoint @JAMASurgery
We compared placebo-controlled and open-label surgical trials to identify when the placebo effect is most powerful @rallamee @KatieEljadi @ImperialNHLI
jamanetwork.com/journals/jam…
Florentina Simader retweeted
Delighted to bring our EAPCI Journal club to 🇬🇧
Discussing #ORBITA2 and the fantastic work by the team:
@rallamee @rajkumar_chris @MikeFoley89 @fiyyazAJ @FloSimader @ProfDFrancis
🚨#EAPCIJournalClub is coming🚨
🎯Discussed trial:
➡️ORBITA-2 (bit.ly/NEJM-Orbita2)
🗓️23 April
⏰18:00 CEST
With:
Dr. Lena Seegers
@rallamee
@ICigalini
@KardiologieHH
‼️Register here‼️
🔗esc365.escardio.org/event/16…
#ByTheFellows #ForTheFellows
Florentina Simader retweeted
Goodbye #ACC from the ORBITA team. Thank you for featuring our work and see you again next year! @FloSimader @ShaynaChotai @MikeFoley89 @rajkumar_chris @fiyyazAJ @mshunshin
Florentina Simader retweeted
Incredibly proud to celebrate @rallamee being awarded the Global CV Future Leader Award 2024 #GCVAwards. An exceptional mentor to us, who has also built a strong team of young researchers at Imperial College @mshunshin @rajkumar_chris @MikeFoley89 @FloSimader @ShaynaChotai – at London, England
Florentina Simader retweeted
Delighted to see our ORBITA-COSMIC design paper published in Eurointervention. Now for the results! My thanks as ever to my supervisors and the incredible ORBITA team @rallamee @mshunshin @rajkumar_chris @fiyyazAJ @FloSimader @drgrahamcole @ProfDFrancis
Have you already metabolized the outcomes of ORBITA 2? Next stop in the ORBITA program is called ORBITA-COSMIC. The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. The ORBITA-COSMIC trial is a randomized, placebo-controlled, double-blind trial investigating the efficacy of the CSR on quantified myocardial perfusion and stable angina. Here is the study rationale and design paper. eurointervention.pcronline.c…
Florentina Simader retweeted
Have you already metabolized the outcomes of ORBITA 2? Next stop in the ORBITA program is called ORBITA-COSMIC. The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. The ORBITA-COSMIC trial is a randomized, placebo-controlled, double-blind trial investigating the efficacy of the CSR on quantified myocardial perfusion and stable angina. Here is the study rationale and design paper. eurointervention.pcronline.c…
Florentina Simader retweeted
Our @ImperialEP reconstructed individual patient data meta-analysis of randomised trials comparing VT ablation to medical therapy is now published in Arrhythmia and Electrophysiology Review @radcliffeCARDIO
In patients with post-infarct VT, catheter ablation reduces mortality
